Member Info for Cashintime

Thanks for that.

I think since they have said that they were in active discussions with potential partners that maybe they would be allowed buy. JS up next maybe for another 750,000 shares. He probably does not hold a broker account and needs to transfer funds first. He is not in the same league as our executive chairman who holds £4.3m worth @ today's prices. I hope he makes a fortune. I am happy to be along for the ride for the moment anyway.

Is mellow online tonight or is it attendi only.

I think a fair price until major news should be 15p. We will see can we pass previous high of what was it 13.5p or thereabouts.

The market likes it with a jump to 12p+ to buy. JS can obviously buy now also and I would say CF ain't finished yet.

Sentiment picking up now and that's what AIM is all about.

CF just after buying 830,000 shares @ 11.68p. Now owns 7.4% of issued share capital. He puts his money where his mouth is and aligns himself with us shareholders here.

Great, we are continuing our upwards momentum this morning. Will we get any hint tonight, probably not but news must be on its way soon on the M&A front with DA working hard on a deal in the background.

Moving up nicely now into the close with 11.4p to buy

Great day here in Poolbeg. If II's are wanting a piece of Hvivo they will be doubtless be eyeing up a stake build in Cathal Friels new focus. Like him or loath him he knows how to create shareholder value and has freshly stated that it will be his main focus. When he builds his stake here as soon as permitted by the nomad we will lunge forward once more. Sentiment is with this share as there is perceived to be a deal looming in the background.

10.75p paid and no original IPO purchasers running to the door. We will be 15p before we know it which would be fair value here considering all that has been achieved so far with minimum cash burn.

Just leave Sanderscam and stop drawing a huge salary in reward for your failure.

Cathal Friel will drive growth in the shareprice, he will put his personal wealth on the line with the purchase of more shares. Something is cooking in the kitchen alright and he had to get the shareprice incentive scheme in place there quick .

Dave Allmond has got the biggest batch that will be worth north of £1.25m and it seems obvious to me he is to bring a M&A opertunity to Poolbeg that will drive growth. Maybe we are going to merge and create a bigger and stronger entity that will be cash generating from the get go and bring us onto Nasdaq later this year. CF has the contacts in all the top 5 big Pharma as he has closed many Hvivo deals with them over the recent years. He will be able to open many doors and I am sure he has already. Poolbeg is going to be a success and I believe that I can make a tidy return for my stake I have built here . I am pleased with the team here including JS as he has not swayed in his enthusiasm for the company. He also has been rewarded with the share incentive scheme and has also promised to buy as soon as allowed by the nomad. News will be delivered soon I am sure.

It won't be long before we in license into a cancer treatment orphan market ready drug which we couple up with Polb 001 . They will compliment each other when coupled together with the ultimate aim of short term cash generation. We are told once more that partnership discussions are ongoing so hopefully news breaking with a good deal soon. They are setting the bar high in the estimation of the potential market to let any partner be aware of the perceived value.

Though this mornings RNS at first was the big one we were waiting and watching for.

I wasn't in Red X myself and had thought about taking a punt this morning for a trade but will hold off. I would expect any Poolbeg upfront payment for a 001 deal to be in the same range. Their cashburn isn't in their favour so and we have proven to be lean burners here in Poolbeg. After starting with £25m cash a couple of years ago we could do with a top up payment from a deal. It is no good to be left in a position of having "multiple shots on goal" and to be stoney broke with it.

This mornings Poolbeg X or twitter comment reminder was to stay tuned, a hint perhaps.

"Stay tuned on the POLB 001 journey - an exciting oral therapy to prevent or treat CRS."

It's amazing that RedX pharma who recently announced a deal similar to the one we are wishing for with Polb 001 have now only increased their market cap by the £10m upfront payment and have got no credit from the market for the projected milestone payments of £870m. They originally increased near 40% but weren't long dropping down to these levels. Is it these auto trades that are doing this to the market lately.

Too much AI is a bad thing and we will never beat them at their own game in the market.

Of course I agree with all these comments and understand that Amyrt did not give the original shareholders the £1.5m to £1.4b returns on paper.

There will be minimum dilution with any in licenses I think but I don't know if the same can be said forsome of the M&A activity that they have in mind. One would hope that the increased perceived value due to new products coming in would protect us here. We can only hold the Poolbeg management to task to ensure our interests are looked after as long-term shareholders. The interest in Polb 001 is seemingly now focused on Oncology rather than RSV so let's hope that a second bite of the cherry or increase at the shots on goal will work out for us. Cathal Friel I feel will hit us with a blockbuster RNS at any time.

Great interview as usual by Dave Allmond and it is clear to see that they have products in mind to in license and are looking at M&A space to list on the Nasdaq.

This is what will drive growth in the short term and bring in new investors here with the deeper pockets.

RedX deal announced this morning might give some indication of the sort of upfront payment. £10m upfront with possible milestones of £870m in royalty payments etc.. I would have thought that they would have increased their market cap by at least £100m but are only managing £35m approx.

I think the first possible news that we get will be in the Orphan drug space which has been hinted at recently. It will be more than likely the reporting of an existing product that will be ready to get out onto the market by the Poolbeg team using their expertise to get grant funding to get it into circulation. It will before a small nominal sum or even free with a royalty paid to the original developer.

It is quiet possible that we will get a partnership on one or more of our existing portfolio at any time.

We are definitely on the pivoting stage to cash generation.

There is another delayed trade for 700K shares bought this morning. Could something be leaking Buys outnumbering sells 3:1. Looking forward to revenue generating news.

Sanderscam has the cap out once more to maintain his lifestyle.

What a useless worm.